GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.
GlaxoSmithKline/Genmab's leukaemia drug ofatumumab (marketed as Arzerra) has hit a setback after failing to meet targets in a late-stage trial assessing its potential in patients with B-cell lymphoma.
GSK said it is now unlikely that ofatumumab will be filed for this indication, given that a combination of the drug plus chemotherapy failed to outperform a rituxan/chemotherapy combo on progression free survival in patients with relapsed/refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma (NHL).
Read the report here: http://bit.ly/1j5bSXD
Source: PharmaTimes online